LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro

被引：0
|
作者：
Ping Xiao
Lin-lin Sun
Jing Wang
Rui-li Han
Qing Ma
Dian-sheng Zhong
机构：
[1] Tianjin Medical University General Hospital,Department of Oncology
[2] Tianjin Lung Cancer Institute,undefined
[3] Tianjin Medical University General Hospital,undefined
来源：
Acta Pharmacologica Sinica | 2015年 / 36卷
关键词：
non small-cell lung cancer; mTOR protein; liver kinase B1; AKT; rapamycin; RAD001; LY294002;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1107 / 1112
页数：5
相关论文
共 50 条
  • [21] Negative regulation of mTOR activity by LKB1-AMPK signaling in non-small cell lung cancer cells
    Dong, Li-xia
    Sun, Lin-lin
    Zhang, Xia
    Pan, Li
    Lian, Lin-juan
    Chen, Zhe
    Zhong, Dian-sheng
    ACTA PHARMACOLOGICA SINICA, 2013, 34 (02) : 314 - 318
  • [22] LKB1 mutations are extremely rare in Korean non-small cell lung cancers
    Kim, Min Jung
    Jin, Guang
    Jheon, Hyo-Sung
    Lee, Sin Yup
    Cha, Sung Ick
    Kim, Chang Ho
    Jung, Tae Noon
    Park, Jae Yong
    CANCER GENETICS AND CYTOGENETICS, 2010, 196 (02) : 204 - 206
  • [23] Glucocorticoid mediated inhibition of LKB1 mutant non-small cell lung cancers
    Huffman, Kenneth E.
    Li, Long Shan
    Carstens, Ryan
    Park, Hyunsil
    Girard, Luc
    Avila, Kimberley
    Wei, Shuguang
    Kollipara, Rahul
    Timmons, Brenda
    Sudderth, Jessica
    Bendris, Nawal
    Kim, Jiyeon
    Villalobos, Pamela
    Fujimoto, Junya
    Schmid, Sandra
    Deberardinis, Ralph J.
    Wistuba, Ignacio
    Heymach, John
    Kittler, Ralf
    Akbay, Esra A.
    Posner, Bruce
    Wang, Yuzhuo
    Lam, Stephen
    Kliewer, Steven A.
    Mangelsdorf, David J.
    Minna, John D.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] LKB1 and KRAS mutations predict resistance to PI3K/Akt inhibitors in non-small cell lung cancer
    Byers, Lauren Averett
    Diao, Lixia
    Wang, Jing
    Girard, Luc
    Peyton, Michael
    Gazdar, Adi
    Groth, Philip
    Paul, Julianne
    Liu, Ningshu
    Kim, Edward S.
    Mauro, David
    Herbst, Roy S.
    Papadimitrakopoulou, Vali
    Coombes, Kevin R.
    Weinstein, John N.
    Minna, John D.
    Heymach, John V.
    CANCER RESEARCH, 2012, 72
  • [25] The potential role of mTOR inhibitors in non-small cell lung cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    ONCOLOGIST, 2008, 13 (02): : 139 - 147
  • [26] LKB1/AMPK/TSC2 signaling pathway alterations in non-small cell lung cancer
    De Aguirre, I
    Zhong, D
    Zhou, W
    Rosell, R
    Vertino, P
    LUNG CANCER, 2005, 49 : S69 - S69
  • [27] LKB1 Mutations in Metastatic Non-Small Cell Lung Cancer (mNSCLC): Prognostic Value in the Real World
    Golozar, A.
    Collins, J.
    Fraeman, K.
    Nordstrom, B.
    Mcewen, R.
    Shire, N.
    Higgs, B.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S223 - S224
  • [28] LKB1 Mutation Status is Associated with Poor Radiation Outcome in Patients with Non-Small Cell Lung Cancer
    Sitthideatphaiboon, P.
    Cobo, A.
    Poteete, A.
    Zhang, F.
    Lui, D.
    Rinsurongkawong, W.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S921 - S921
  • [29] Metabolic barriers in non-small cell lung cancer with LKB1 and/or KEAP1 mutations for immunotherapeutic strategies
    Tanaka, Ichidai
    Koyama, Junji
    Itoigawa, Hideyuki
    Hayai, Shunsaku
    Morise, Masahiro
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] Effects of phenformin in LKB1/KRAS mutated non-small cell lung cancer patient derived xenograft
    Moro, Massimo
    Roz, Luca
    Caserini, Roberto
    Pastorino, Ugo
    Sozzi, Gabriella
    CANCER RESEARCH, 2014, 74 (19)
12345